



Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.  
PALYNZIQ SOSY (Pegvaliase) Prior Authorization (PA)  
Pharmacy Benefits Prior Authorization Help Desk  
Length of Authorizations: Initial- 6 months; Continuation- 12 months

**Instructions:**

This form is used by Kaiser Permanente and/or participating providers for coverage of **PALYNZIQ SOSY (Pegvaliase)**. Please complete all sections, incomplete forms will delay processing. Fax this form back to Kaiser Permanente within 24 hours fax: 1-866-331-2104. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless all sections are complete.**

KP-MAS Formulary can be found at: <http://www.providers.kaiserpermanente.org/mas/formulary.html>

**1 – Patient Information**

Patient Name: \_\_\_\_\_ Kaiser Medical ID#: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

**2 – Prescriber Information**

Prescriber Name: \_\_\_\_\_ Specialty: \_\_\_\_\_ NPI: \_\_\_\_\_

Prescriber Address: \_\_\_\_\_

Prescriber Phone #: \_\_\_\_\_ Prescriber Fax #: \_\_\_\_\_

**3 – Pharmacy Information**

Pharmacy Name: \_\_\_\_\_ Pharmacy NPI: \_\_\_\_\_

Pharmacy Phone # \_\_\_\_\_ Pharmacy Fax #: \_\_\_\_\_

**4 – Drug Therapy Requested**

Drug 1: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

Drug 2: Name/Strength/Formulation: \_\_\_\_\_

Sig: \_\_\_\_\_

### 5– Diagnosis/Clinical Criteria

1. Is this request for initial or continuing therapy?  
 Initial therapy                       Continuing therapy, State date: \_\_\_\_\_
2. Indicate the Member’s diagnosis for the requested medication: \_\_\_\_\_
3. Is the member ≥18 years of age? **AND**  
 No  Yes
4. Documented diagnosis of classical phenylketonuria (PKU) confirmed by metabolic specialist? **AND**  
 No  Yes
5. Does the member have a pre-treatment baseline phenylalanine (Phe) level >600 micromol//L? **AND**  
 No  Yes
6. Dose does not exceed maximum FDA-approved dosing? **AND**  
 No  Yes
7. Not using concurrent Kuvan (sapropterin); sapropterin should be discontinued prior to initiation of pegvaliase-pqpz  
 No  Yes

**For Continuation of Therapy, Please Respond to Additional Questions Below:**

1. Documentation of positive clinical response? **AND**  
 No  Yes
2. Office visit or telephone visit with a specialist within the past 12 months?  
 No  Yes

### 6 – Prescriber Sign-Off

**Additional Information – Please submit chart notes/medical records for the patient that are applicable to this request. Provide any additional supporting information that should be taken into consideration:**

---

**I certify that the information provided is accurate. Supporting documentation is available for State audits.**

**Prescriber Signature:**

**Date:**

Please Note: This document contains confidential information, including protected health information, intended for a specific individual and purpose. The information is private and legally protected by law, including HIPAA. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any action in reliance on the contents of this telecopied information is strictly prohibited. Please notify sender if document was not intended for receipt by your facility